The study provides evidence that pediatric ePRO collection through a digital platform is feasible; it supports, but does not test, the hypothesis that age-tailored content, clinician acknowledgment, and workflow integration could improve sustained symptom reporting, communication, and ultimately supportive or palliative care.

The evidence supports moderate risk discrimination based on registry-derived clinical and treatment-pattern associations; it is only an inference that, after prospective external validation with appropriately timed imaging, pathological, and molecular variables, such a model could improve staging intensity or individualized management, and no treatment benefit is demonstrated.

The study provides evidence that inconsistent NF1 documentation can impede computational phenotyping; it is reasonable but unproven to infer that implementing and validating the proposed lexicon could improve surveillance, trial identification, and real-world evidence generation, with no direct evidence here of improved treatment or patient outcomes.

The review provides evidence that genetic testing, radiological assessment, and management of parenteral-nutrition complications may improve diagnosis, prognostic counseling, and supportive care; any resulting reduction in sepsis or mortality is a plausible inference rather than an intervention effect demonstrated by this study, and no oncology-directed therapeutic hypothesis is supported.

The evidence does not establish either surgical route as superior for preventing cerebellar mutism syndrome; as an inference, future approach selection or risk-reduction strategies may need to focus on factors beyond the transvermian-versus-telovelar distinction.

The reported observations support maximal safe endoscopic resection as a potentially effective local treatment for anatomically localized nasal skull-base RDD; however, any added value of postoperative corticosteroids remains unproven and requires systematic study.

The evidence supports HMGA2 primarily as a diagnostic triage marker; it is only an inference, not tested here, that DICER1-associated disruption of microRNA/let-7 regulation produces early HMGA2 overexpression that might eventually represent a therapeutic pathway vulnerability.

The reported evidence supports ALBI as an objective prognostic stratification tool; it may, by inference, improve treatment selection or trial stratification, but the record does not show that ALBI-guided care changes therapy, toxicity, or survival, and pediatric applicability is unestablished.

The study provides evidence for an association between severe cerebral desaturation and postoperative biomarker elevation; it supports, but does not test, the hypothesis that rScO2-guided strategies that prevent or promptly correct desaturation could reduce perioperative neurological injury.

The record provides no therapeutic efficacy evidence; it proposes that identifying potentially maladaptive or beneficial patterns of family accommodation could, as a future inference, inform family-centered psychosocial interventions and survivorship care.

The evidence supports BALF caspase-4 as a candidate correlate of pulmonary inflammatory activity; it is only an inference that caspase-4 could enable severity assessment or represent a treatment target, as no intervention, causal pathway experiment, outcome prediction, or pediatric-oncology population was evaluated.

The record provides observational evidence that a stepwise carbapenem-sparing empiric antibiotic protocol can often be used without escalation in this adult center; it may therefore support antimicrobial stewardship, but any benefit, safety, or applicability in pediatric oncology remains an untested inference because pediatric patients were excluded and regimens were not independently compared.